Odd Erik Johansen
Position: Associated Post doctoral researcher, MD
Phone:
Email:

PubMed registered articles

 

Author network for Odd Erik Johansen by COREMINE medical


Publications 2017

Chilton R, Tikkanen I, Hehnke U, Woerle HJ, Johansen OE (2017)
Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension
Diabetes Obes Metab (in press)
PubMed 28387058

Škrtić M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, Woerle HJ, Johansen OE, Broedl UC, Hach T, Silverman M, Cherney DZ (2017)
Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
Diabetologia (in press)
PubMed 28374067

Zinman B, Inzucchi SE, Lachin JM, Wanner C, Fitchett D, Kohler S, Mattheus M, Woerle HJ, Broedl UC, Johansen OE, Albers GW, Diener HC, EMPA-REG OUTCOME Investigators (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) (2017)
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
Stroke, 48 (5), 1218-1225
PubMed 28386035

Publications 2016

Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME® trial investigators (2016)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
Eur Heart J, 37 (19), 1526-34
PubMed 26819227

Lehrke M, Leiter LA, Hehnke U, Thiemann S, Bhandari A, Meinicke T, Johansen OE (2016)
Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials
J Diabetes Complications, 30 (7), 1378-84
PubMed 27396241

Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, Broedl UC, Johansen OE (2016)
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication
Hypertension, 68 (6), 1355-1364
PubMed 27977392

Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, Broedl UC, Johansen OE (2016)
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
Diab Vasc Dis Res, 13 (2), 119-26
PubMed 26873905

Tikkanen I, Chilton R, Johansen OE (2016)
Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension
Curr Opin Nephrol Hypertens, 25 (2), 81-6
PubMed 26808705

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, EMPA-REG OUTCOME Investigators (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
N Engl J Med, 375 (4), 323-34
PubMed 27299675

Publications 2015

Cherney D, Cooper M, Tikkanen I, Crowe S, Johansen OE, Lund SS, Woerle HJ, Broedl UC, Hach T (2015)
4B.01: CONTRASTING INFLUENCES OF RENAL FUNCTION ON BLOOD PRESSURE AND HBA1C REDUCTIONS WITH EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES AND HYPERTENSION
J Hypertens, 33 Suppl 1, e53
PubMed 26102847

Chilton R, Tikkanen I, Cannon CP, Crowe S, Hach T, Woerle HJ, Broedl UC, Johansen OE (2015)
4B.02: THE SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR EMPAGLIFLOZIN REDUCES BLOOD PRESSURE AND MARKERS OF ARTERIAL STIFFNESS AND VASCULAR RESISTANCE IN TYPE 2 DIABETES
J Hypertens, 33 Suppl 1, e53
PubMed 26102848

Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE (2015)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
Diabetes Obes Metab, 17 (12), 1180-93
PubMed 26343814

Chilton R, Tikkanen I, Crowe S, Johansen OE, Broedl UC, Woerle HJ, Hach T (2015)
4B.03: EMPAGLIFLOZIN REDUCES SYSTOLIC BLOOD PRESSURE IN DIPPER AND NON-DIPPER PATIENTS WITH TYPE 2 DIABETES AND HYPERTENSION
J Hypertens, 33 Suppl 1, e53
PubMed 26102849

Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE (2015)
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials
Diab Vasc Dis Res, 12 (2), 90-100
PubMed 25589482

Johansen OE (2015)
Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach
World J Diabetes, 6 (9), 1092-6
PubMed 26265995

Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ (2015)
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
Diab Vasc Dis Res, 12 (3), 164-74
PubMed 25780262

Neeland IJ, McGuire DK, Eliasson B, Ridderstråle M, Zeller C, Woerle HJ, Broedl UC, Johansen OE (2015)
Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study
Diabetes Ther, 6 (4), 635-642
PubMed 26608511

Ofstad AP, Urheim S, Dalen H, Orvik E, Birkeland KI, Gullestad L, W Fagerland M, Johansen OE, Aakhus S (2015)
Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross-sectional comparison with non-diabetic weight-matched controls
J Diabetes, 7 (6), 779-90
PubMed 25350248

Perkins BA, Cherney DZ, Soleymanlou N, Lee JA, Partridge H, Tschirhart H, Zinman B, Mazze R, Fagan N, Kaspers S, Woerle HJ, Broedl UC, Johansen OE (2015)
Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes
PLoS One, 10 (11), e0141085
PubMed 26544192

Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen OE, Woerle HJ, Broedl UC, Kaspers S (2015)
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)
Diabetes Obes Metab, 17 (10), 928-35
PubMed 26080652

Rosenstock J, Marx N, Neubacher D, Seck T, Patel S, Woerle HJ, Johansen OE (2015)
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
Cardiovasc Diabetol, 14, 57
PubMed 25990013

Ulimoen GR, Ofstad AP, Endresen K, Gullestad L, Johansen OE, Borthne A (2015)
Low-dose CT coronary angiography for assessment of coronary artery disease in patients with type 2 diabetes--a cross-sectional study
BMC Cardiovasc Disord, 15, 147
PubMed 26573616

Zinman B, Ahrén B, Neubacher D, Patel S, Woerle HJ, Johansen OE (2015)
Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis
Can J Diabetes, 40 (1), 50-7
PubMed 26474870

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
N Engl J Med, 373 (22), 2117-28
PubMed 26378978

Publications 2014

Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC (2014)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
Cardiovasc Diabetol, 13, 28
PubMed 24475922

Cherney DZ, Perkins BA, Soleymanlou N, Xiao F, Zimpelmann J, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M, Burns KD (2014)
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
Kidney Int, 86 (5), 1057-8
PubMed 25360497

Gerner T, Johansen OE, Olufsen M, Torjesen PA, Tveit A (2014)
The post-prandial pattern of gut hormones is related to magnitude of weight-loss following gastric bypass surgery: a case-control study
Scand J Clin Lab Invest, 74 (3), 213-8
PubMed 24472033

Johansen OE, Boehm BO, Grill V, Torjesen PA, Bhattacharya S, Patel S, Wetzel K, Woerle HJ (2014)
C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study
Diabetes Care, 37 (1), e11-2
PubMed 24356601

Lehrke M, Marx N, Patel S, Seck T, Crowe S, Cheng K, von Eynatten M, Johansen OE (2014)
Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
Clin Ther, 36 (8), 1130-46
PubMed 25015594

Ofstad AP, Johansen OE, Gullestad L, Birkeland KI, Orvik E, Fagerland MW, Urheim S, Aakhus S (2014)
Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi-intervention in type 2 diabetes: the randomized controlled Asker and Bærum Cardiovascular Diabetes (ABCD) study
Am Heart J, 168 (3), 280-288.e2
PubMed 25173538

Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, Fagan NM, Kaspers S, Woerle HJ, Broedl UC, Johansen OE (2014)
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial
Diabetes Care, 37 (5), 1480-3
PubMed 24595630

Skrtić M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, Woerle HJ, Johansen OE, Broedl UC, Hach T, Silverman M, Cherney DZ (2014)
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
Diabetologia, 57 (12), 2599-602
PubMed 25280671

Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, Bluhmki E, Hantel S, Kempthorne-Rawson J, Newman J, Johansen OE, Woerle HJ, Broedl UC (2014)
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
Cardiovasc Diabetol, 13, 102
PubMed 24943000

Publications 2013

Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M (2013)
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
Circulation, 129 (5), 587-97
PubMed 24334175

Ofstad AP, Gullestad L, Orvik E, Aakhus S, Endresen K, Ueland T, Aukrust P, Fagerland MW, Birkeland KI, Johansen OE (2013)
Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum Cardiovascular Diabetes (ABCD) cohort study
Cardiovasc Diabetol, 12, 126
PubMed 23987834

Rosenstock J, Marx N, Johansen OE, Wörle HJ, CAROLINA Steering Committee (2013)
Cardiovascular effects of diabetes drugs: making the dark ages brighter with Carolina
Ann Intern Med, 158 (6), 499
PubMed 23553039

Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, Johansen OE, Woerle HJ (2013)
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial
Diab Vasc Dis Res, 10 (4), 289-301
PubMed 23449634

Publications 2012

Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ (2012)
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
Cardiovasc Diabetol, 11, 3
PubMed 22234149

Ueland T, Aukrust P, Aakhus S, Smith C, Endresen K, Birkeland KI, Gullestad L, Johansen OE (2012)
Activin A and cardiovascular disease in type 2 diabetes mellitus
Diab Vasc Dis Res, 9 (3), 234-7
PubMed 22234949

Publications 2011

Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Løberg EM, Haaland T, Konopski Z, Wium C, Aasheim ET, Johansen OE, Aukrust P, Halvorsen B, Birkeland KI (2011)
Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies
Eur J Endocrinol, 166 (3), 503-10
PubMed 22170794

Publications 2010

Hallén J, Johansen OE, Birkeland KI, Gullestad L, Aakhus S, Endresen K, Tjora S, Jaffe AS, Atar D (2010)
Determinants and prognostic implications of cardiac troponin T measured by a sensitive assay in type 2 diabetes mellitus
Cardiovasc Diabetol, 9, 52
PubMed 20843304

Kontny F, Risanger T, Bye A, Arnesen Ø, Johansen OE, TELMIMORE Study Investigators (2010)
Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care
Vasc Health Risk Manag, 6, 31-8
PubMed 20191081

Sørensen M, Johansen OE (2010)
Idiopathic reactive hypoglycaemia - prevalence and effect of fibre on glucose excursions
Scand J Clin Lab Invest, 70 (6), 385-91
PubMed 20509823

Publications 2009

Johansen OE, Birkeland KI, Jørgensen AP, Orvik E, Sørgård B, Torjussen BR, Ueland T, Aukrust P, Gullestad L (2009)
Diabetic foot ulcer burden may be modified by high-dose atorvastatin: A 6-month randomized controlled pilot trial
J Diabetes, 1 (3), 182-7
PubMed 20923537

Johansen OE, Vanberg PJ, Kilhovd BK, Jørgensen AP (2009)
Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
Vasc Health Risk Manag, 5 (1), 121-8
PubMed 19436668

Publications 2008

Johansen OE (2008)
[Urogenital problems and female Internet users]
Tidsskr Nor Laegeforen, 128 (24), 2845-6
PubMed 19092957

Johansen OE, Brustad E, Enger S, Tveit A (2008)
Prevalence of abnormal glucose metabolism in atrial fibrillation: a case control study in 75-year old subjects
Cardiovasc Diabetol, 7, 28
PubMed 18822173

Johansen OE, Qvigstad E (2008)
Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg
Adv Ther, 25 (6), 525-51
PubMed 18568306

Johansen OE, Whitfield R (2008)
Exenatide may aggravate moderate diabetic renal impairment: a case report
Br J Clin Pharmacol, 66 (4), 568-9
PubMed 18537959

Publications 2007

Johansen OE (2007)
[Natural preparations against climacteric problems?]
Tidsskr Nor Laegeforen, 127 (6), 764-5
PubMed 17363992

Johansen OE (2007)
Cardiovascular disease and type 2 diabetes mellitus: a multifaceted symbiosis
Scand J Clin Lab Invest, 67 (8), 786-800
PubMed 17852797

Johansen OE, Birkeland KI (2007)
Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review
Am J Cardiovasc Drugs, 7 (5), 319-35
PubMed 17953471

Johansen OE, Birkeland KI, Orvik E, Flesland Ø, Wergeland R, Ueland T, Smith C, Endresen K, Aukrust P, Gullestad L (2007)
Inflammation and coronary angiography in asymptomatic type 2 diabetic subjects
Scand J Clin Lab Invest, 67 (3), 306-16
PubMed 17454845

Johansen OE, Bjurö T, Endresen K, Blaasaas KG, Birkeland K, Aakhus S, Gullestad L (2007)
Heart rate adjustments and analysis of recovery patterns of ST-segment depression in type 2 diabetes
Int J Cardiol, 127 (1), 129-32
PubMed 17532067

Johansen OE, Gullestad L, Blaasaas KG, Orvik E, Birkeland KI (2007)
Effects of structured hospital-based care compared with standard care for Type 2 diabetes-The Asker and Baerum Cardiovascular Diabetes Study, a randomized trial
Diabet Med, 24 (9), 1019-27
PubMed 17509068

Publications 2006

Johansen OE, Birkeland KI, Brustad E, Aaser E, Lindahl AK, Midha R, Ueland T, Aukrust P, Gullestad L (2006)
Undiagnosed dysglycaemia and inflammation in cardiovascular disease
Eur J Clin Invest, 36 (8), 544-51
PubMed 16893376

Johansen OE, Jørgensen AP (2006)
[Glitazone treatment of type 2 diabetes mellitus]
Tidsskr Nor Laegeforen, 126 (15), 1928-30
PubMed 16915317

Starkopf J, Hegna S, Johansen OE, Munch-Ellingsen J, Mjøs OD, Ytrehus K (2006)
In vivo chronic carvedilol treatment in rats attenuates ex vivo regional infarction of the heart
Scand Cardiovasc J, 40 (4), 240-7
PubMed 16914417

Publications 2005

Johansen OE, Birkeland KI (2005)
[Misleading about insulin administration to patients with diabetes]
Tidsskr Nor Laegeforen, 125 (16), 2247; author reply 2247
PubMed 16138161

Publications 2003

Johansen OE, Birkeland KI (2003)
Preventing macrovascular disease in patients with type 2 diabetes mellitus
Am J Cardiovasc Drugs, 3 (4), 283-97
PubMed 14728081